Safirstein Metcalf LLP:  DaVita, Inc. Misled Shareholders According to a Recently Filed Action - DVA

NEW YORK, April 14, 2017 -- Safirstein Metcalf LLP announces that a class action complaint was filed against DaVita Inc. (“DaVita”) (NYSE:DVA) in the U.S. District Court for the District of Colorado. The complaint is brought on behalf of all purchasers of DaVita securities between August 5, 2015 and October 21, 2016 (the “Class Period”) for alleged violations of the Securities Exchange Act of 1934.  Safirstein Metcalf is investigating potential breaches of fiduciary duty by management of DaVita resulting from allegations that management may have issued materially misleading business information to the investing public.

If you would like more information about this matter, please contact Sheila Feerick at 1-800-221-0015, or email [email protected]. 

According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using the American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.

About Safirstein Metcalf LLP

Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection.  All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY  10001
1-800-221-0015